To identify additional genes underlying growth or selumetinib responses in NF1-mutant, PRC2-intact neurofibroma cells, sgRNA enrichment or depletion after vehicle control or selumetinib treatment (T10) was compared to sgRNA abundance prior to treatment (T0) (Fig. 3a, Table 1, and Supplementary Data 8). Here, NF1 is linked to plexiform neurofibroma.